The goal of this clinical trial is to learn how Ozanimod drug can be administered to the healthy subjects via transdermal delivery system (TDS, patch) to achieve better drug absorption and delivery than via oral capsules (Zeposia). Researchers will compare two administered routes of Ozanimod TDS and oral Zeposia in drug pharmacokinetics, tolerability and safety. Participants will either take one capsule only or wear a patch on his/her arm for 7 days, and blood samples will be collected to measure drug concentrations and local skin reactions will be also observed.
Age range
18 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Plasma Pharmacokinetic- AUC 0-t (Ozanimod, CC112273, CC1084037)
Timeframe: 15 days
Plasma Pharmacokinetic- AUC 0-∞ (Ozanimod, CC112273, CC1084037)
Timeframe: 15 days
Plasma Pharmacokinetic- Cmax (Ozanimod, CC112273, CC1084037)
Timeframe: 15 days
Plasma Pharmacokinetic- Tmax (Ozanimod, CC112273, CC1084037)
Timeframe: 15 days
Plasma Pharmacokinetic- T 1/2 (Ozanimod, CC112273, CC1084037)
Timeframe: 15 days
Plasma Pharmacokinetic- MTR(Ozanimod, CC112273, CC1084037)
Timeframe: 15 days
Plasma Pharmacokinetic-Lambda z(λz) (Ozanimod, CC112273, CC1084037)
Timeframe: 15 days